38 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 38 of 38 clinical reviews.
Evidence-based tadalafil dosing guide for adults aged 30 to 49, covering on-demand and daily regimens for erectile dysfunction and BPH, with trial data, dose adjustments, and clinical considerations.
Tadalafil (Cialis) is taken by mouth, not by injection. Learn how tadalafil works as an oral PDE5 inhibitor, when penile self-injection therapy applies instead, and how these two ED treatment pathways compare.
A deep dive into how tadalafil affects sleep architecture, nocturnal erections, sleep apnea, and overnight PDE5 inhibition. Includes clinical trial data, dosing considerations, and practical guidance.
An evidence-based breakdown of every clinically significant drug-drug interaction for tadalafil (Cialis), including nitrates, alpha-blockers, CYP3A4 inhibitors, antihypertensives, and more. Includes mechanisms, clinical thresholds, and management guidance.
A guide to tadalafil dosing in patients 65 and older, covering starting doses, renal and hepatic adjustments, drug interactions, falls risk, and when to reconsider treatment.
A guide to tadalafil dosing for men aged 18-29, covering on-demand vs. Daily regimens, fertility considerations, safety data, and how to talk to your prescriber.
A guide to tadalafil food and supplement interactions, including grapefruit, alcohol, nitrates, and common supplements that alter PDE5 inhibitor pharmacokinetics.
A clinician-level review of tadalafil's pipeline: new delivery systems, combination therapies, emerging indications, and the trials reshaping how this PDE5 inhibitor will be used beyond erectile dysfunction and BPH.
Evidence-based monitoring guide for tadalafil (Cialis) use in adults 65 and older, covering renal function, blood pressure, drug interactions, falls risk, and deprescribing timelines.
A guide to tadalafil dosing, safety, and drug interactions in transplant recipients, people living with HIV, older adults, and other special populations. Includes trial data, FDA label guidance, and clinical decision frameworks.
A clinical overview of tadalafil manufacturing origins, generic entry, FDA shortage events, and current supply chain status for Cialis and its generic equivalents.
Evidence-based guide to managing a missed dose of daily tadalafil (Cialis). Covers pharmacokinetics, clinical timing windows, and when to skip vs. double up.
Evidence-based monitoring guide for tadalafil (Cialis) in adults aged 50 to 64, covering cardiovascular screening, renal and hepatic labs, blood pressure targets, drug interactions, and when to adjust dosing.
Evidence-based monitoring guide for young adults aged 18-29 taking tadalafil (Cialis) for erectile dysfunction, covering labs, cardiovascular checks, fertility considerations, and follow-up intervals.
A deep dive into tadalafil safety during pregnancy and breastfeeding, covering FDA classification, animal data, placental transfer, PDE5 physiology in pregnancy, and clinical decision-making for women who take Cialis for PAH or other indications.
A clinician-grade review of tadalafil real-world evidence from registries, claims databases, and observational cohorts covering erectile dysfunction, BPH, cardiovascular safety, and adherence patterns.
A physician-level review of tadalafil's regulatory approvals, patent expirations, generic availability, and prescribing classifications across the US, EU, Canada, and the UK.
Evidence-based safety profile of tadalafil (Cialis) in adults aged 30 to 49, covering side effects, cardiovascular risk, drug interactions, daily vs. on-demand dosing, and clinical monitoring.
Evidence-based safety guide for tadalafil (Cialis) in adults aged 50 to 64, covering cardiovascular risk, drug interactions, dosing adjustments, and monitoring recommendations.
A guide to tadalafil safety in men aged 18 to 29, covering cardiovascular risks, fertility effects, drug interactions, daily vs. On-demand dosing, and when to see a doctor.
Evidence-based review of tadalafil safety in geriatric patients, covering dose adjustments, drug interactions, fall risk, renal considerations, and deprescribing strategies for men over 65.
A clinical history of tadalafil from early PDE5 research through FDA approval, mechanism of action, key trials, and the evolution of daily dosing for ED and BPH.
A physician-level review of tadalafil (Cialis) and cancer risk signals, covering prostate, bladder, and melanoma data, PDE5 inhibitor pharmacology, and current FDA labeling status.
How to adjust tadalafil (Cialis) doses in patients with mild or moderate hepatic impairment, including FDA label limits, pharmacokinetic data, and clinical guidance for prescribers.
Evidence-based guide to tadalafil (Cialis) dosing adjustments in chronic kidney disease and dialysis, including mechanism of action, pharmacokinetics, and safety data with PubMed-cited references.
A physician-level breakdown of how tadalafil (Cialis) works, from nitric oxide release to PDE5 inhibition, smooth muscle relaxation, and the pharmacokinetic properties that set it apart from sildenafil and vardenafil.
Evidence-based monitoring schedule for Cialis (tadalafil) including baseline labs, follow-up exams, and ongoing safety checks for erectile dysfunction and BPH patients.
A guide to tadalafil (Cialis) overdose management, including symptoms, treatment protocols, pharmacokinetics at supratherapeutic doses, and when to seek emergency care.
A complete timeline of Cialis (tadalafil) patents, Paragraph IV challenges, FDA generic approvals, and what the shift to generic competition means for pricing and access.
A clinician-level guide to tadalafil pharmacogenomics, covering CYP3A4/3A5 polymorphisms, PDE5A variants, nitric-oxide pathway genetics, and how genetic testing can guide dosing of Cialis for erectile dysfunction and BPH.
A clinician-grade review of tadalafil (Cialis) pharmacokinetics covering absorption, distribution, metabolism via CYP3A4, and the 17.5-hour elimination half-life that defines its 36-hour clinical window.
What is established, what is plausible but unproven, and what remains unresolved in the postmarketing safety record for tadalafil (Cialis), including FDA label actions and the drug's absolute nitrate contraindication.
How to store Cialis (tadalafil) correctly, what affects tablet stability, and when expired tadalafil loses potency. FDA data, ICH guidelines, and pharmacokinetic evidence reviewed.
A comparison of compounded tadalafil vs branded Cialis covering bioequivalence, FDA regulatory status, dosing, cost, safety, and how to choose the right formulation for ED or BPH.
State Medicaid coverage for Cialis (tadalafil) varies widely. Learn which states cover it, prior authorization requirements, step therapy rules, appeal processes, and how to access affordable tadalafil through Medicaid.
A complete guide to UnitedHealthcare coverage for Cialis (tadalafil), including formulary tier, prior authorization criteria, step therapy requirements, appeal steps, and cash-pay alternatives.
Evidence-based guide to safely discontinuing tadalafil (Cialis) for ED or BPH, including tapering considerations, rebound risks, and when to consult your prescriber.
Long-term data show tadalafil may lower MACE and improve endothelial function in select patients, but nitrate use remains an absolute contraindication.